ProQR Therapeutics NV

09/09/2021 | Press release | Distributed by Public on 09/09/2021 03:02

Euretina (2021) DG Birch. Phase 1b/2 interim results of QR-421a RNA therapy in retinitis pigmentosa due to mutations in USH2A